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Abstract
Alpha-particle radiopharmaceutical therapy (αRPT) is currently enjoying increasing attention as a
viable alternative to chemotherapy for targeting of disseminated micrometastatic disease. In
theory, αRPT can be personalized through pre-therapeutic imaging and dosimetry. However, in
practice, given the particularities of α-particle emissions, a dosimetric methodology that
accurately predicts the thresholds for organ toxicity has not been reported. This is in part due to
the fact that the biological effects caused by α-particle radiation differ markedly from the effects
caused by traditional external beam (photon or electron) radiation or β-particle emitting
radiopharmaceuticals. The concept of relative biological effectiveness (RBE) is used to quantify
the ratio of absorbed doses required to achieve a given biological response with alpha particles
versus a reference radiation (typically a beta emitter or external beam radiation). However, as
conventionally defined, the RBE varies as a function of absorbed dose and therefore a single RBE
value is limited in its utility because it cannot be used to predict response over a wide range of
absorbed doses. Therefore, efforts are underway to standardize bioeffect modeling for different
fractionation schemes and dose rates for both nuclear medicine and external beam radiotherapy.
Given the preponderant use of external beams of radiation compared to nuclear medicine in cancer
therapy, the more clinically relevant quantity, the 2 Gy equieffective dose, EQD2(α/β), has
recently been proposed by the ICRU. In concert with EQD2(α/β), we introduce a new, redefined
RBE quantity, named RBE2(α/β), as the ratio of the two linear coefficients that characterize the α
particle absorbed dose-response curve and the low-LET megavoltage photon 2 Gy fraction
equieffective dose-response curve. The theoretical framework for the proposed new formalism is
presented along with its application to experimental data obtained from irradiation of a breast
cancer cell line. Radiobiological parameters are obtained using the linear quadratic model to fit
cell survival data for MDA-MB-231 human breast cancer cells that were irradiated with either α
particles or a single fraction of low-LET 137Cs γ rays. From these, the linear coefficient for both
the biologically effective dose (BED) and the EQD2(α/β) response lines were derived for
fractionated irradiation. The standard RBE calculation, using the traditional single fraction
reference radiation, gave RBE values that ranged from 2.4 for a surviving fraction of 0.82–6.0 for
a surviving fraction of 0.02, while the dose-independent RBE2(4.6) value was 4.5 for all surviving
fraction values. Furthermore, bioeffect modeling with RBE2(α/β) and EQD2(α/β) demonstrated
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the capacity to predict the surviving fraction of cells irradiated with acute and fractionated low-
LET radiation, α particles and chronic exponentially decreasing dose rates of low-LET radiation.
RBE2(α/β) is independent of absorbed dose for α-particle emitters and it provides a more logical
framework for data reporting and conversion to equieffective dose than the conventional dose-
dependent definition of RBE. Moreover, it provides a much needed foundation for the ongoing
development of an α-particle dosimetry paradigm and will facilitate the use of tolerance dose data
available from external beam radiation therapy, thereby helping to develop αRPT as a single
modality as well as for combination therapies.
INTRODUCTION
Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry,
and the increased availability of alpha emitters appropriate for clinical use, have recently led
to a resurgence of preclinical studies and a number of clinical trials using
radiopharmaceuticals labeled with these radionuclides (1–5). The same characteristics that
make these radiopharmaceuticals attractive for targeting disseminated disease, namely the
high-linear energy transfer (LET) and short range (<80 μm in water) of the α particles, also
render their dosimetry complex. This is a serious issue as one of the major advantages of
radiopharmaceutical therapy over chemotherapy is the ability to tailor treatment to a higher
level of personalization. This is often done by quantitative imaging of a pretherapeutic
quantity of radiopharmaceutical or an imaging surrogate in the patient at several time points
to determine organ activities as a function of time. These data are used to calculate average
organ absorbed doses per unit administered activity and ultimately the maximum tolerable
activity that can be administered safely. However, because of the short range of α particles,
nonuniformity in the activity uptake at the suborgan or functional subunit level will result in
a nonuniform absorbed dose distribution, which may lead to localized toxicities that affect
the organ as a whole in a manner inconsistent with radiotoxicity predicted by estimations of
the average absorbed dose. In recognition of this fact, the Medical Internal Radiation Dose
(MIRD) Committee has recommended the use of small-scale and/or microdosimetry for α-
particle emitters and other radionuclides that impart high-LET type damage (6, 7), and
efforts are ongoing in this direction (8–11) that attempt to translate macroscopically
measured activity to cell- and subunit scale dosimetry.
Efforts are also currently underway to standardize a framework for bioeffect modeling of
different fractionation schemes in external-beam radiation therapy, differing absorbed dose
rates in nuclear medicine therapy and different LET radiations used in external beam
therapies and nuclear medicine (i.e., protons, carbon ions, Auger electrons, α particles). The
equieffective dose, EQDX(α/β), has recently been proposed by the International
Commission on Radiation Units and Measurements (ICRU) as the standard quantity for
bioeffect modeling of responses to therapeutic applications of ionizing radiation (12); in this
notation, X is the fraction size and α/β is the ratio of the linear-quadratic model of cell
survival parameters that characterize cell type response to low-LET radiation. The
commonly used biologically effective dose (BED) (13, 14), represented by EQD0(α/β) in
the EQDX(α/β) notation, would seem to be a natural choice for such standardization from a
theoretic standpoint, as it uses the already existing linear parameter from the linear-quadratic
formalism. However, most clinically relevant tissue responses have been characterized with
acutely delivered 2 Gy fractions of low-LET radiations and consequently clinicians are well
versed in tissue responses to 2 Gy fractions. In this context, the ICRU (12) recommends
using the EQD2(α/β) form of the equieffective dose. Regardless of which reference is used
in the EQDX(α/β) formalism, the lethal effects of low-LET radiation are exponentially
dependent on EQDX(α/β). This means that cell survival curves are a log-linear function (i.e.,
single exponential) of EQDX(α/β) for low-LET radiation. At absorbed doses and dose-rates
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relevant to radionuclide and external-beam therapy, cell survival curves for α-particle
radiation are a log-linear function of absorbed dose. Therefore, we propose defining the α-
particle relative biological effectiveness RBE2(α/β) as the ratio of the two linear coefficients
that characterize the α-particle absorbed dose-response curve and the low-LET megavoltage
photon 2 Gy fraction equieffective dose-response curve. In other words, the low-LET
equieffective (2 Gy fraction equivalent) dose for α-particle radiation can be obtained by
simply multiplying the absorbed dose (from α-particle radiation) by the same RBE2(α/β)
value, no matter the absorbed dose. Further, we recommend reporting RBE2(α/β) instead of
the conventionally defined RBE, which does vary with absorbed dose.
METHODS
Conventional Definition of Relative Biological Effectiveness for High-LET Radiation with
Exponential Dose Response
According to the widely-accepted linear-quadratic model (15), which forms the basis for
radiobiological modeling for most irradiation conditions except extremely high dose rates,
the surviving fraction (SF) of cells receiving an absorbed dose from low-LET radiation, DL,
is:
(1)
The parameters α and β are known, respectively, as the linear and quadratic radiobiological
parameters and are in principle specific to a given cell type. However, for α particles [or
DNA-incorporated Auger electron emitters (16, 17), another high-LET type radiation], the
response to the absorbed dose, DH, is exponential (i.e., linear on a semilog plot):
(2)
here, κ is the radiobiological parameter that characterizes the response of a given cell line to
α-particle irradiation. The relative biological effectiveness is designed to relate the absorbed
dose of the reference radiation (often low-LET delivered acutely) and absorbed dose of the
test radiation (in this case high-LET α particles) that are required to cause equal biological
effect (18): either a same surviving fraction of cells for cellular in vitro studies or a same
measure of toxicity or therapeutic efficacy in organs or tumors, respectively. The basic
equation that defines this concept is:
(3)
This principle is illustrated in Fig. 1, where a same given surviving fraction of cells from the
same cell line is obtained after delivery of an absorbed dose from either a high-LET
radiation such as an α particle (DH) or a low-LET radiation (DL), given as a single fraction.
The ratio between the two doses is the RBE. However, it is apparent that this ratio depends
on the surviving fraction of cells chosen, or equivalently on the absorbed doses DH and/or
DL.
No dose-independent resolution for the value of RBE is possible (Fig. 2); RBE is potentially
equal to a range of values for the same cell line and is most often reported as such. The
conundrum caused by the range of RBE for a given cell line is made concrete by
establishing RBEmin (19) and RBEmax (20) for dose-response modeling. In that approach,
the RBEmin such as it has been defined formulaically is undefined for cell survival curves
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for α-particle radiation. Consequently, in practice RBEmin and RBEmax are often taken as
the limits of the measured RBE values, which may or may not correspond to the theoretical
limits. By setting Eq. (1) equal to Eq. (2), a relationship between DH and DL is established:
(4)
Substituting Eq. (4) into Eq. (3), the RBE can be expressed as a function of DH:
(5)
Alternatively, by expressing RBE as a function of DL, a more useful equation is established:
(6)
For a fractionated regimen of low-LET radiation, when the time interval between fractions is
short relative to the doubling time of the cells, the surviving fraction of cells is given by:
(7)
for a number, n, fractions of dL absorbed dose per fraction (Fig. 2b). The RBE can be
derived in a similar manner for a fractionated low-LET regimen by setting Eq. (2) equal to
Eq. (7), and for an equivalent surviving fraction of cells, we have:
(8)
And the RBE for a reference fractionated low-LET regime is:
(9)
The conventional definition of the RBE given by Eq. (6) poses problems when it is used to
predict biological response primarily because it depends on absorbed dose. It also assumes
that the reference radiation is a single fraction of low-LET radiation (e.g., 137Cs γ rays) that
is delivered acutely, and that all low-LET radiations are equally effective. This definition of
reference radiation is often not well suited for the external beam therapy community and
even less so for nuclear medicine. Indeed, outside of stereotactic radiosurgery and high dose
brachytherapy, single fractions of high dose delivered punctually have little basis as a frame
of reference; consequently reporting values relating α-particle dose to such a regimen makes
little practical sense. A more universal, more easily understandable reference radiation
would clearly be advantageous. The fractionated formalism given by Eq. (9) has this
potential, assuming a standard dose per fraction can be adopted.
The EQDX(α/β) Framework
Two major schools of thought have emerged in radiation therapy for dose response
modeling that accounts for dose rate or fractionation differences, BED and EQD2(α/β).
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These are rooted in radiobiology. The BED has been used most often in nuclear medicine,
yet both approaches account for absorbed dose delivered over the time frames specific to
radiopharmaceutical therapy. However, recently the ICRU has promulgated the use of the
equieffective dose EQDX(α/β) for bioeffect modeling of radiation responses (12). EQDX(α/
β) is defined as the total absorbed dose delivered by the external beam reference treatment
plan of fraction size X that leads to the same biological effect as a test treatment plan that is
conducted with absorbed dose per fraction dL and total absorbed dose DL according to a
relation adapted from the Withers formula (21):
(10)
It was proposed that 2 Gy fractions of megavoltage X rays, EQD2(α/β), should be the
reference (12). Accordingly, given this new standard, the RBE should be redefined with
EQD2(α/β) as the reference radiation. In this formalism, the BED is the same as EQD0(α/β).
While not as elegant or natural as the use of BED [or EQD0(α/β)] from a theoretic
standpoint, the rationale behind this choice is that 2 Gy fractions are the most common
standard for external beam radiotherapy and thus the biological effects are best understood
by the treating physicians and by the radiotherapy community in general; it is, simply put, a
more clinically relevant standard. From a linearity standpoint, which is the primary concern
when addressing the issue of RBE for high-LET (α particle) radiations, the two choices
[BED or EQD2(α/β)] are equivalent. Normal organ toxicity has often been correlated with
BED; for example, this has been used in the context of renal toxicity caused by targeted
radionuclide therapy (22, 23). However, since the BED and EQD2(α/β) are related by a
constant coefficient for a given cell line, tissue or organ, the response relationships
correlated to the BED will also exist for EQD2(α/β).
RBE2(α/β) for HIGH-LET Radiations in Radiopharmaceutical Therapy
Since the EQDX(α/β) has been chosen as the standard on the basis of being the common
denominator of understanding, a logical step is to accommodate high-LET radiations (α
particles, DNA-incorporated Auger electron emitters) in the EQDX formalism:
(11)
By substituting Eq. (9) for RBE into Eq. (11):
(12)
Eq. (12) establishes a linear relation between EQDX(α/β) and DH; the coefficient of
proportionality is named RBEX(α/β):
(13)
Where, equivalent to Eq. (11),
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(14)
And, more specifically:
(14b)
The interpretation of this result is that the EQD2(α/β) standard is understood not as the “2
Gy fraction equivalent” specific to a particular modality, but as the “2 Gy fractions of low-
LET megavoltage external beam equivalent” as the standard for all radiation types. The
visual clarification of this EQDX(/) formalism is shown in Fig. 3. With respect to this
standard, the relative biological effectiveness of the high-LET α particles is constant for the
specified cell line or tissue; this constant is denoted RBE2(α/β).
Potentially, the RBEmax could also be used as a linear conversion constant in a manner
analogous to the proposed RBE2(α/β) quantity; in fact in the EQDX(α/β) schema the
RBEmax would logically be renamed “RBE0(α/β)”. Should the BED, rather than the
EQD2(α/β) be deemed a more appropriate standard, the RBE0(α/β) quantity would follow
as the more appropriate linear conversion for high-LETα-particle radiation.
(15)
Application to Cell Lines
The survival curves for a human breast cancer cell line MDA-MB-231, exposed to α-
particle radiation or low-LET 137Cs gamma-ray radiation (0.5 Gy/min) were measured by
colony formation assay. Details regarding the cell culture, radiolabeling, colony formation
and dosimetry have been previously published (24, 25). Briefly, for α-particle radiation,
MDA-MB-231 cells were exposed to nonspecific Rituximab-labeled 213Bi (concentration
range from 2.0 to 40.0 μCi/ml). Cells were incubated overnight, washed with PBS and
transferred to Petri dishes for colony growth. The radiation absorbed doses from 213Bi
(range from 0.21–4.3 Gy) were estimated assuming the non-targeting α-particle radiation to
be uniformly distributed and absorbed in the volume containing the cells.
Comparison with Low-LET Preclinical Radiopharmaceutical Therapy Studies
There are examples in the literature wherein an RBE is derived by comparing the biological
effect, in vivo, of low-LET radiation delivered by a β-emitter labeled radiopharmaceutical
(i.e., the reference radiation) characterized by a linear-quadratic cell survival curve in a
semilog plot with an α-emitter labeled radiopharmaceutical (26, 27). In such a circumstance,
RBEXα/β is not directly available, but may be calculated by first converting the absorbed
dose from low-LET RPT, DRPT, to an EQDX(α/β) and then by applying the developed
formalism. The conversion to DRPT from EQDX(α/β) has been previously described in the
context of combination external beam-RPT therapy (28) and is derived in a manner
analogous to the Wither’s formula (Eq. 10), namely by equating the BED for the different
modalities to each other. The BED for external beam therapy is:
(16)
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where DXRT is the total absorbed dose from external beam (XRT) and dXRT is the absorbed
dose per fraction. The formula for BED using low-LET RPT is (14, 29):
(17)
where G(T) is the Lea-Catcheside G-factor in the LQ response which accounts for DNA
repair that occurs during chronic irradiation, as is the case in low-LET RPT where the
absorbed dose is delivered continuously over a period of several hours or days. The
expression for the G-factor is given by:
(18)
where t and w are integration variables representing time, and T is the integration limit time
point, i.e., the integral is from 0 to T in time. For simple dose rate kinetics, such as mono-
exponential fits, this equation reduces to simpler analytic forms; however, even in its most
general form the G-factor may be resolved numerically (30). Using the BED as a bridge and
setting Eq. (16) equal to Eq. (17) with the dose per fraction dXRT = 2 Gy and therefore DXRT
= EQD2(α/β), we obtain:
(19)
As shown in Eq. (19), the EQD2(α/β) expression for a low LET-emitter labeled
radiopharmaceutical is a function of the radiopharmaceutical absorbed dose, DRPT, and the
G-factor. The G-factor, in turn, depends on a radiobiological parameter, μ, which represents
the rate of DNA single-strand break (SSB) repair, assumed exponential, and on the dose-rate
kinetic profile during the irradiation duration. The dependencies shown in Eq. (19)
underscore the fact that the ratio between the low-LET and high-LET RPT absorbed doses,
and therefore an RBE defined as such, depends on the absorbed dose as well as the dose
rate. However, once EQD2(α/β) has been calculated, the invariant RBE2(α/β) value may be
obtained by combining Eq. (13), where DH is the absorbed dose for the alpha-emitter labeled
radiopharmaceutical calculated with Eq. (19):
(20)
More specifically, while the ratio of DRPT and DH, sometimes reported as the RBE value in
the literature (26, 27) depends on the absorbed dose and dose rate, and the ratio of EQD2(α/
β) to low-LET RPT absorbed dose, DRPT, also depends on those same factors, the product of
those dependencies shown in Eq. (20) does not depend on either factor and RBE2(α/β) is
indeed invariant.
RESULTS
Application to Cell Lines
The surviving fraction of MDA-MB-231 cells is plotted in Fig. 4. The error bars indicate the
standard deviation for the two studies. The data were plotted using the ROOT physics
analysis software (31) and fit with the Migrad algorithm inherited from the Minuit libraries
(32). The parameters to the linear-quadratic fit to the low-LET data are: α = (0.187 ± 0.020)
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Gy−1 and β = (0.0408 ± 0.0054) Gy−2 with a fit correlation of R2 = 0.99, while the high-LET
parameter value is κ = (1.21 ± 0.02) Gy−1 with a fit correlation of R2 = 0.99. From these
values, the derived quantities and their uncertainties were calculated: α/β = (4.6 ± 1.1) Gy,
RBE0(4.6) = (6.5 ± 0.8), and RBE2(4.6) = (4.5 ± 0.6), while the traditional RBE value
varies from 2.4 to 6.0.
Illustration of EQDX(α/β) Equivalence
To illustrate the impact of the formalism presented here, surviving fraction values were
calculated for different patterns of delivering absorbed dose from different radiation types:
(1) acute (single fraction) external beam; (2) 2 Gy per fraction external beam; (3) high-LET
αRPT; and (4) and traditional (low-LET) β-particle RPT. The radiobiological parameters for
the MDA-MB-231 cell line were used for all cases. However, in the case of traditional β-
particle RPT, a simple exponential decrease in the dose rate with a half-life, Tλ, of 8 h and a
repair half-life, Tλ, of 0.5 h were assumed. For a simple exponential fit to the dose rate, Eq.
(18) reduces to:
(21)
Consequently, for the chosen parameters, G(∞) = 0.0588, for the β-particle RPT. The
resulting SF values were plotted as a function of absorbed dose in Fig. 5a. The absorbed
doses were then converted to EQD2(α/β) using Eq. (10) for the acute radiation; Eq. (12) for
the α-particle radiation; and Eq. (19) for the β-particle RPT radiation and plotted in Fig. 5b.
As expected, the EQD2(α/β) results all fall along a same line in the semilog plots,
demonstrating the utility of the EQDX(α/β) formalism and the advantage of correlating
response with EQD2(α/β).
DISCUSSION
The purpose of this article is to develop and recommend a consistent manner of presenting
α-particle RBE values to the scientific and clinical communities. The 2 Gy fraction
equivalent of external beam radiation formalism proposed herein would discourage the use
of giving RBE values for a range of doses that may or not be relevant (may or may not
include a theoretical RBEmax) and that may be subsequently taken and applied out of
context (for a different dose range than for those published) by the community. Historically,
attempts have been made to report only single values of RBE for ease of application (16);
however, no single standard emerged successfully and the choice of basis varied between
D50, D37 or D10. Most authors stated the endpoint – although not always and because of the
lack of consistency, the RBE value would be extracted from the article and the endpoint lost
in the process. With the advent of an official standard and nomenclature, we hope that the
proposed single value formalism will enjoy widespread acceptance.
According to the strict definition of relative biological effectiveness (18), the test and
reference radiations should be delivered in an identical manner with the exception of the
radiation type. However, this is often experimentally difficult, particularly in the context of
targeted radionuclide therapies. Implicit in the RBEX(α/β) formalism proposed here is the
separation of dose rate and LET effects. This is logical given that the dose-rate dependence
of the response to low-LET radiation is already implicit within the “2 Gy equivalent”
concept for this type of radiation. More generally, as pointed out by the ICRU (12), the
EQD2(α/β) standard should be considered not just the standard for external beams of low-
LET radiations, but for all radiation types, in which case the α-particle RBE, re-named the
RBE2(α/β), an absorbed dose-independent quantity, should also be the standard. By such a
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definition, importantly, reported values for use by the general community gain significantly
in transparency and enable straightforward application of documented results.
While this treatise focuses mainly on α particles, the proposed use of RBE2(α/β) as the
relevant reported RBE value is eminently logical for other high-LET radiations used in
nuclear medicine, such as Auger electrons, which present similar log-linear dose-response
curves when the Auger emitter is incorporated into DNA in the cell nucleus, as well as those
encountered in external beam, such as protons or carbon ion (33) radiations, which are
characterized by a linear-quadratic response curve. Much work has already been done by
Dale and colleagues (19, 20, 34) incorporating RBE into the BED formalism; however, still
within the context of an absorbed dose-dependent RBE between two extreme limits RBEmax
at low absorbed dose per fraction and RBEmin at very high absorbed dose per fraction.
From the perspective of αRPT, a single RBE value to convert absorbed dose to equieffective
dose would facilitate progress towards an effective paradigm for bioeffect modeling in
αRPT. Specifically, such a tool would be used to validate the RBE-adjusted equivalence of
normal organ radiotoxicity thresholds in pre-clinical and clinical cases, as has been done for
kidney toxicity in β-emitter RPT and external beam therapy using the BED as a
standardizing quantity (22, 23). This in turn along with the spatial macro-to-micro
conversion methodology would provide the justification for combination dosimetry for
combination therapies, which include αRPT. This is a highly desirable goal as αRPT is
especially suited for micro-metastases, which are not identified in external beam therapy and
often receive sub-therapeutic doses from β-emitting radiopharmaceuticals. Combination
strategies using different β emitters (35, 36) or using β-emitters in conjunction with external
beam have been proposed (28); however, for optimal therapy targeting as large a range of
tumor sizes as possible, αRPT would be the ideal complement to other therapies. In general,
accurate dosimetry is fundamental to radiation therapies to ensure an optimal, safe and
effective treatment. The use of population averaged standard anatomy based approaches that
provide a single absorbed dose value, is detrimental to the effective treatment of the
individual patient, especially if one considers the nonlinearity of tumor cell kill and response
to administered therapeutic quantities.
The present formalism assumes that the linear-quadratic (LQ) and linear models are valid for
the photon/β-emitter dose response and α-particle dose response, respectively. While the LQ
model is generally recognized as valid and forms the basis for much of the normal organ
dose-toxicity thresholds that have been established, it is also generally recognized that high
dose rates or fractions such as those present in high dose rate brachytherapy,
hypofractionated therapy or stereotactic radiosurgery have cellular responses that can depart
from the linear-quadratic model. Several supplementary or alternative models have been
proposed to account for these high dose rates (37–39). To date none have commanded
unequivocal consensus. Similarly, the log-linear quality of the α-particle dose-response
curve is suspect at higher dose; the α-particle curves tend to be concave up on the semilog
plots. This is possibly due to the statistical fluctuations and the stochastic nature of the α-
particle energy deposition or due to the different relative distributions of the radionuclide
(40). Additionally, a theoretical quadratic term should exist in the α-particle cell survival
curve, since an important fraction of the damage is delivered by delta-ray electrons.
However, to date this has not been observed experimentally, and departures from the log-
linear curve tend to be concave up as noted previously, rather than concave down. In all
cases, the formalism presented here is amenable to variations in the models used to describe
the cellular dose-response curves, as the fundamental principle of defining and reporting
RBE with respect to EQD2(α/β) remains.
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In the 213Bi experiments conducted in this article, we have assumed that the mean absorbed
dose to the cultured cells is equal to the mean absorbed dose to the culture medium
from 213Bi. Given that (1) the individual cells are much smaller than the range of the α
emissions, (2) the antibody does not bind to the cells and (3) the cells exist as individuals in
suspension in the medium, this is a reasonable approximation that has been substantiated by
Monte Carlo simulations (data not shown). However, there are imprecisions in activity
measurement and assumptions in the methodology that may influence the data presented in
Fig. 4. Dose-response measurements using a broad beam of α particles would give cleaner,
more accurate results (41). It should also be noted that RBE2(α/β) (or generic RBE) values
can be sensitive to experimental conditions such as temperature, pressure, CO2
concentration, pH, cell cycle phase, etc. Every effort should be made to control these
variables as tightly as possible. Nevertheless, as a proof of principle, the results presented
here illustrate the concept and potential value of an absorbed dose-independent, dose-rate-
adjusted relative biological effectiveness parameter.
Particular attention should be made to the issue of dose nonuniformity when applying the
model to larger scale collections of cells, such as in tumors or normal organs. The relative
short range of α particles means that any nonuniformity of uptake will most likely result in
nonuniformity of absorbed dose. Just as a single absorbed dose value may not well represent
the complexity of the absorbed dose distribution or the biological response, the single
RBE2(α/β) value may not be sufficient. In the case of tumors, the equivalent uniform dose
(42) has shown promise as a single value more representative of biological response (43,
44), but a more diverse representation such as a dose-volume histogram with associated
RBE2(α/β) values may still present a clearer picture. In the case of normal organs, as
previously mentioned, the MIRD Committee has recommended micro- or small-scale
dosimetry (6), and models exist where absorbed dose values are calculated for different
compartments corresponding to different cell types or spatial distributions (8, 9) (e.g.,
proximal tubules and glomeruli for the kidney) to which RBE2(α/β) values may be
attributed.
On a similar note, for protracted therapies, such as with 225Ac, which has a 10-day half-life,
additional modifications to the formalism that allow for cellular repopulation may be
relevant and this has not been taken into account. However, here too, this is probably best
addressed by incorporating the repopulation factor into the small-scale modeling which
attributes the absorbed dose values to the cell population and only subsequently calculates
the respective RBE2(α/β) values.
A significant practical consideration concerns the origin of the α, β and κ values necessary
for the calculation of RBE2(α/β). Although there is substantial documentation regarding the
radiobiological parameters in the literature, the picture is far from complete. If the
radiobiological parameters are unknown, it may still be necessary to compare efficacy over a
range of absorbed doses from high-LET and low-LET radiations to identify the
radiobiological parameters. Concerning the conversion of RPT-derived RBE values to the
RBEX(α/β) formalism, once α, β, DRPT and G are known, as is often the case, Eq. (14) may
be used to calculate, κ and in so doing, link in vivo response end points to a cell-line
surviving fraction end point. In general, the proposed RBE2(α/β) does not immediately
resolve any outstanding issues regarding the validity of in vitro vs. in vivo radiobiological
parameter values, however, by reducing the RBE to a single dose-independent quantity, the
formalism does eliminate one of the confounding factors. Consequently, this will better
enable the identification of potential radiobiological differences between in vitro and in vivo
end points.
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Finally, we have not considered the dependence of RBE2(α/β) on the energy of the α-
particles emitted by the radionuclide. Because RBE depends on LET and LET depends on
the α-particle energy, the RBE differs for particles emitted by different radionuclides (45). A
number of possibilities can account for this dependence, for example: (1) RBE2(α/β) is
determined experimentally as a function of initial α-particle energy over the range of
energies emitted by the various α emitters (~2–10 MeV) (45) or (2) a more theoretical
microdosimetric approach where RBE2(α/β) takes into account the changes in LET as the α-
particles traverse the cell population.
CONCLUSIONS
Consistent with the ICRU framework for bioeffect modeling with EQD2(α/β), the α-particle
relative biological effectiveness RBE2(α/β) is defined as the ratio of the two linear
coefficients that characterize the α-particle absorbed dose-response curve and the low-LET
megavoltage photon 2 Gy fraction equieffective dose-response curve. RBE2(α/β) thus
defined, is independent of absorbed dose and provides a more logical formalism than the
conventional absorbed dose-dependent definition of RBE. Moreover, RBE2(α/β) provides a
much needed foundation for the ongoing development of an α-particle bioeffect modeling
paradigm as well as for rational (i.e., safe and effective) dosimetrically-based combination
therapies.
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FIG. 1.
Semilog plot of theoretical cell survival curves for low-LET radiation such as β particles
(linear-quadratic, blue symbols) and high-LET radiation such as α particles (linear, red
symbols). For a given surviving fraction SF, the RBE is the ratio of the respective absorbed
doses DL and DH corresponding to the SF.
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FIG. 2.
Panel a: Relative biological effectiveness [as defined by Eq. (6)] as a function of absorbed
dose from low-LET radiation. RBE(DL → 0) = RBEmax = κ/α. Panel b: Illustration of Eq.
(7), the surviving fraction of cells for a fractionated dose regimen (dL = 2 Gy, green)
compared to a single fraction (blue).
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FIG. 3.
Graphical interpretation of the RBE0(α/β) and RBE2(α/β) concepts on a semilog plot. The
red line represents the linear response to high-LET radiations such as α particles (Eq. 2),
while the other three curves relate to the low-LET response. The dotted dark-blue line is the
linear quadratic dose-response curve for low-LET radiations such as X rays and β particles
(Eq. 1), the green line is the linear dose-response to infinitely small fraction size and the
light-blue line is the linear dose-response to a fraction size of 2 Gy. The values of DH, DL,
EQD2(α/β) and BED for a given SF are denoted on the abscissa. RBE0(α/β) is the ratio
between DH and EQD0(α/β), RBE2(α/β) is the ratio between DH and EQD2(α/β); these
values are constant for all DH, DL and SF.
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FIG. 4.
Measured response of cells that were acutely irradiated with 137Cs γ rays (blue circles) or α
particles from 213Bi (red triangles). Data were least squares fitted to Eq. (1) (dark-blue lines)
or Eq. 2 (red lines). Using the experimental values of α, β and κ, the green line is the
projected linear dose-response to infinitely small fraction size [Eq. (9), dL = 0] and the light-
blue line is the linear dose-response to a fraction size of 2 Gy [Eq. (9), dL = 2 Gy]. Results
are presented for MDA-MB-231, a human breast cancer cell line.
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FIG. 5.
Dose-response curves for MDA-MB-231 cells for different radiation delivery patterns and
types when plotted as a function of D (panel A) and EQD2(α/β) (panel B). The curves in
panel A are plotted using Eqs. (1) and (2). This demonstrates the convergence of the dose
response when surviving fraction is plotted as function of EQDX(α/β).
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